baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Knock-Out Genmab AS/ DE000SW3NYR2 /

31/05/2024 12:53:53	Chg.0.00	Bid17:20:14	Ask17:20:14	Underlying	Strike price	Expiration date	Option type
4.81EUR	0.00%	4.75 Bid Size: 3,000	4.80 Ask Size: 3,000	-	3,720.2266 DKK	31/12/2078	Put

GlobeNewswire 29/05 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 21/05 Genmab Completes Acquisition of ProfoundBio

GlobeNewswire 21/05 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 17/05 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

GlobeNewswire 14/05 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...

GlobeNewswire 14/05 Immatics Announces First Quarter 2024 Financial Results and Business Update

GlobeNewswire 06/05 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 02/05 Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire 30/04 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...

GlobeNewswire 22/04 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 07/04 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...

GlobeNewswire 03/04 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

GlobeNewswire 20/03 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 20/03 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

GlobeNewswire 11/03 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...

GlobeNewswire 07/03 BioNTech Announces Planned Retirement of Sean Marett

GlobeNewswire 06/03 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...

GlobeNewswire 04/03 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...

GlobeNewswire 14/02 Genmab Announces Initiation of Share Buy-Back Program

GlobeNewswire 14/02 Genmab Publishes 2023 Annual Report

GlobeNewswire 08/02 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...

GlobeNewswire 31/01 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...

GlobeNewswire 22/01 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...

GlobeNewswire 09/01 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

Soc. Generale Knock-Out Genmab AS/ DE000SW3NYR2 /

If you wish to receive reply to your feedback, please provide your email address.